Letter to the Editor: Salidroside in ulcerative colitis - neuroimmune regulatory mechanisms and clinical translation prospects

doi:10.3748/wjg.123972

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 42

This Article

(3)

(4)

(0)

(26)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 14, 2026; 32(42): 123972
Published online Nov 14, 2026. doi: 10.3748/wjg.123972

Letter to the Editor: Salidroside in ulcerative colitis - neuroimmune regulatory mechanisms and clinical translation prospects

Yao-Feng Zhou, Jia-Wang Yan, Fu-Shan Tang

Yao-Feng Zhou, Jia-Wang Yan, Fu-Shan Tang, Clinical Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China

Author contributions: Zhou YF contributed to the initial drafting and revision of the manuscript; Yan JW participated in discussions and contributed to the revisions; Tang FS contributed to idea generation, manuscript revision, and provided supervision; and all authors have reviewed and approved the final version of the manuscript.

AI contribution statement: Artificial intelligence (AI) tools were used exclusively for language editing to improve the clarity and readability of this manuscript. The authors carefully reviewed, verified, and edited all AI-assisted content and accept full responsibility for the accuracy, originality, and scientific integrity of the manuscript.

Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.

Corresponding author: Fu-Shan Tang, Full Professor, Clinical Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com.

Received: June 3, 2026
Revised: July 28, 2026
Accepted: August 31, 2026
Published online: November 14, 2026
Processing time: 111 Days and 23.5 Hours

Core Tip

Core Tip: This article presents a novel perspective based on the “enteric neuro-glial-immune regulatory network” and elucidates the potential mechanisms by which salidroside exerts anti-inflammatory, immunomodulatory, and intestinal mucosal barrier-protective effects through the regulation of enteric glial cells. Furthermore, by discussing the challenges associated with clinical translation and formulation optimization strategies, this article explores the potential application of salidroside as a multi-target therapeutic agent for precision treatment of ulcerative colitis.